Insurance
Home›Insurance›Health Insurance›Elevance reaffirms 2026 benefit expense ratio guidance…
Elevance reaffirms 2026 benefit expense ratio guidance at 90.2%
The insurer says the reaffirmation, filed Sept. 10, indicates medical utilization and specialty pharmacy costs are tracking within its 2026 pricing assumptions as fall and early 2027 renewals are set.
Elevance Health reaffirmed its full-year 2026 benefit expense ratio guidance at 90.2%, plus or minus 50 basis points, signaling that medical utilization and specialty pharmacy costs are tracking in line with what the company built into its pricing. The carrier filed the update via an 8-K with the SEC on September 10, and linked the ratio target to its expected claims experience through mid-year.
Alongside the benefit expense ratio, Elevance said it expects to reaffirm full-year adjusted earnings guidance of at least $27 per diluted share in meetings with investors and analysts over the coming weeks. The company noted that a benefit expense ratio of 90.2% implies it expects to pay roughly 90 cents of every premium dollar in medical claims, leaving limited room to cover administrative costs, taxes, and profit.
Elevance said the ratio targets are closely tied to the timing of group health renewals, with fall and the early 2027 cycle being finalized around this point in the calendar. It cited a Q2 2026 benefit expense ratio of 89.7%, up 80 basis points year over year, attributing the increase to elevated medical cost trends in its government business (Medicaid and Medicare), partially offset by stronger individual ACA performance.
The insurer also reiterated that the main cost drivers are not new, with specialty pharmacy costs led by GLP-1 medications remaining a named factor in its earnings commentary. Elevance processes pharmacy claims through its Carelon subsidiary, and it pointed to government segment medical cost trend, including Medicaid acuity levels and reimbursement rates that have not fully caught up, as a key headwind.